Topic
Tuberculosis screening tests
💡 What You Need to Know
- Purpose of Screening: Tuberculosis (TB) screening tests are crucial for identifying individuals with latent TB infection (LTBI) or active TB disease, even before symptoms appear.
- Common Tests: The two primary methods are the Tuberculin Skin Test (TST), also known as the Mantoux test, and Interferon-Gamma Release Assays (IGRAs), such as QuantiFERON-TB Gold Plus or T-SPOT.TB.
- Latent vs. Active TB: Screening helps differentiate between LTBI, where the bacteria are present but inactive, and active TB disease, which is contagious and requires immediate treatment.
- High-Risk Populations: Screening is particularly recommended for individuals with close contact to active TB cases, those born in or who frequently travel to high TB burden countries, healthcare workers, and immunocompromised individuals.
🤒 Associated Symptoms
- Persistent Cough: A cough lasting three weeks or longer, often producing sputum, is a key indicator for active pulmonary TB.
- Fever and Chills: Unexplained low-grade fever, particularly in the afternoon, accompanied by chills, can prompt TB investigation.
- Night Sweats: Drenching sweats occurring during sleep are a classic systemic symptom associated with active TB.
- Unexplained Weight Loss: Significant and unintentional loss of body weight is a common constitutional symptom of active TB disease.
- Fatigue and Weakness: Persistent feelings of tiredness, malaise, and general weakness can be indicative of an underlying infection like TB.
- Chest Pain: Pain in the chest, especially when breathing or coughing, may suggest pleural involvement or extensive lung disease.
- Hemoptysis: Coughing up blood or blood-streaked sputum is a serious symptom that warrants immediate medical evaluation for active TB.
🛡 Crucial Precautions
- TST Reading Window: For Tuberculin Skin Tests (TST), ensure the patient returns for the reading within 48 to 72 hours after the injection to accurately assess the reaction.
- Injection Site Care (TST): Advise patients not to scratch, rub, or cover the injection site with a bandage. Normal bathing is permissible.
- Prior BCG Vaccination: Inform the healthcare provider if the patient has received the Bacillus Calmette-Guérin (BCG) vaccine, as it can cause a false-positive TST result. IGRAs are generally preferred in BCG-vaccinated individuals.
- Immunosuppression Disclosure: Patients must disclose any conditions or medications that suppress the immune system (e.g., HIV, organ transplant, corticosteroids), as these can lead to a false-negative TST result.
- Blood Sample Integrity (IGRA): For Interferon-Gamma Release Assays (IGRAs), ensure proper blood collection technique and timely processing to maintain sample integrity and accurate results.
- Avoid Repeat TST Too Soon: If a TST is negative, a second TST (two-step TST) may be performed 1-3 weeks later for certain populations to detect boosted reactions, but generally, avoid frequent, unnecessary repeat testing.
🍽 Dietary Directions & Restrictions
- No Specific Restrictions: Tuberculosis screening tests (TST and IGRA) generally do not require any specific dietary restrictions or fasting prior to the procedure.
- Normal Hydration: Patients should maintain their usual hydration levels unless otherwise instructed for other concurrent medical reasons.
- Medication Intake: Continue all prescribed medications as usual, unless specifically advised by a healthcare provider, as they typically do not interfere with the test results.
⚠️ Attendant Guidelines
- Positive TST/IGRA Interpretation: A positive result indicates exposure to TB bacteria and the presence of either latent TB infection or active TB disease, requiring further diagnostic evaluation.
- Further Diagnostic Steps: A positive screening test necessitates additional tests, such as a chest X-ray, sputum smear, and culture, to rule out active TB disease.
- False Negative Possibility: Be aware that false-negative results can occur, particularly in immunocompromised individuals, very young children, or those with recent TB infection.
- False Positive Possibility (TST): False-positive TST results can occur in individuals who have received the BCG vaccine or have been infected with non-tuberculous mycobacteria. IGRAs are less affected by BCG vaccination.
- Contact Tracing: If active TB is diagnosed, public health guidelines require contact tracing to identify and screen individuals who may have been exposed.
🩺 Physician's Perspective
- Clinical Context is Key: Interpretation of TB screening results must always be done within the context of the patient's clinical history, risk factors, and epidemiological exposure.
- Differentiating LTBI from Active TB: A positive screening test alone is insufficient for diagnosing active TB; a thorough clinical evaluation, including imaging and microbiological studies, is essential.
- Treatment for LTBI: For individuals diagnosed with latent TB infection, preventive therapy is crucial to reduce the risk of progression to active disease, especially in high-risk groups.
- Public Health Imperative: Effective TB screening and management are vital components of global TB control strategies, aiming to reduce transmission and incidence.
- Guideline Adherence: Physicians should adhere to national and international guidelines for TB screening, diagnosis, and treatment to ensure optimal patient outcomes and public health safety.
🎓 Academic & Nursing Corner
- TST Administration Technique: Master the Mantoux method for intradermal injection, ensuring a precise 0.1 mL dose of PPD to create a distinct wheal (6-10 mm in diameter).
- Accurate TST Reading: Learn to palpate and measure the diameter of induration (firm, raised area), not erythema (redness), in millimeters, within the specified 48-72 hour window.
- Patient Education on Results: Provide clear, concise explanations to patients about what a positive or negative result means and the necessary follow-up steps.
- IGRA Blood Draw Protocol: Understand the specific requirements for IGRA blood collection, including specialized tubes and timely transport to the laboratory to prevent degradation.
- Infection Control Principles: Reinforce strict infection control measures when caring for patients with suspected or confirmed active TB, including airborne precautions.
- Documentation: Meticulously document all aspects of the screening process, including test type, date, time, results, and patient education provided.
🔬 Clinical Reference Index
- Tuberculin Skin Test (TST): A delayed-type hypersensitivity reaction to purified protein derivative (PPD) of *Mycobacterium tuberculosis*, indicating prior exposure.
- Interferon-Gamma Release Assays (IGRAs): *In vitro* blood tests that measure the release of interferon-gamma by T-cells in response to specific *M. tuberculosis* antigens (ESAT-6, CFP-10), which are absent from BCG and most non-tuberculous mycobacteria.
- Induration Measurement: The critical parameter for TST interpretation, with specific cut-off points (e.g., ≥5 mm, ≥10 mm, ≥15 mm) depending on risk factors.
- Two-Step TST: Used for initial screening of individuals who will be tested periodically (e.g., healthcare workers) to detect boosted reactions from remote infection.
- Sensitivity and Specificity: IGRAs generally offer higher specificity than TST, especially in BCG-vaccinated populations, and comparable sensitivity.
- CDC and WHO Guidelines: Refer to current Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO) guidelines for comprehensive recommendations on TB screening and management.